FDA Panel Agrees GSK’s RSV Vaccine Is Effective But Wants More Data Before Approval

02 Mar 2023

Advisory committee votes 10-2 that data are adequate to support safety of the vaccine in adults 60 and older, voicing concern about small potential safety signals after co-administration with influenza shot. Several members question rush to market with just one season of data.

Advisory committee votes in support of GSK's RSV vaccine for older adults but wants US FDA to delay approval • Source: Shutterstock

FDA Panel Agrees GSK’s RSV Vaccine Is Effective But Wants More Data Before Approval

More from US FDA Performance Tracker

More from Regulatory Trackers